Figure 4. Cumulative net costs and cumulative number of life-years saved of universal testing and immediate ART for all HIV-infected patients (UTT) compared to the current rollout in South Africa of ART at CD4 count ≤350 cells/µl, as predicted with model D.

(A) Cumulative net costs; (B) cumulative number of life-years saved. Grey lines represent 100 individual model runs illustrating stochastic variation; black lines are averages over 1,000 model runs. Error bars reflect ranges due to uncertainty in the parameter values that were quantified based on fitting the model to data. Costs and life-years saved were discounted at an annual rate of 3%.